Oleuropein aglycone protects against pyroglutamylated-3 amyloid-&#223; toxicity: biochemical, epigenetic and functional correlates by Luccarini, Ilaria et al.
lable at ScienceDirect
Neurobiology of Aging 36 (2015) 648e663Contents lists avaiNeurobiology of Aging
journal homepage: www.elsevier .com/locate/neuagingOleuropein aglycone protects against pyroglutamylated-3 amyloid-ß
toxicity: biochemical, epigenetic and functional correlates
Ilaria Luccarini a,1, Cristina Grossi a,1, Stefania Rigacci b, Elisabetta Coppi c,
Anna Maria Pugliese a, Daniela Pantano a, Giancarlo la Marca a,d, Teresa Ed Dami a,d,
Andrea Berti b, Massimo Stefani b, Fiorella Casamenti a,*
aDepartment of Neuroscience, Psychology, Drug Research and Child Health, Division of Pharmacology and Toxicology, University of Florence,
Florence, Italy
bDepartment of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Florence, Italy
cDepartment of Health Sciences, University of Florence, Florence, Italy
dDepartment of NEUROFARBA, Newborn Screening, Clinical Chemistry and Pharmacology Lab, Meyer Children’s University Hospital, Florence, Italya r t i c l e i n f o
Article history:
Received 16 May 2014
Received in revised form 1 August 2014
Accepted 28 August 2014
Available online 6 September 2014
Keywords:
Alzheimer’s disease
Epigenetics
Oleuropein aglycone
Long-term potentiation
Pyroglutamylated-3 Aß
Glutaminyl cyclase
TgCRND8 mice* Corresponding author at: Department of Neur
Research and Child Health, Division of Pharmacology
Florence, 50139 Florence, Italy. Tel.: þ39 055 4271242
E-mail address: fiorella.casamenti@unifi.it (F. Casam
1 These authors contributed equally to this work.
0197-4580/$ e see front matter  2015 Elsevier Inc. A
http://dx.doi.org/10.1016/j.neurobiolaging.2014.08.029a b s t r a c t
Amyloid-ß (Aß) fragments, oligomeric Aß aggregates, and pyroglutamylated-Aß peptides, as well as
epigenetic mechanisms and autophagy dysfunction all appear to contribute in various ways to Alz-
heimer’s disease progression. We previously showed that dietary supplementation of oleuropein agly-
cone, a natural phenol abundant in the extra virgin olive oil, can be protective by reducing Aß42 deposits
in the brain of young and middle-aged TgCRND8 mice. Here, we extended our study to aged TgCRND8
mice showing increased pE3-Aß in the brain deposits. We report that oleuropein aglycone is active
against glutaminylcyclase-catalyzed pE3-Aß generation reducing enzyme expression and interferes both
with Aß42 and pE3-Aß aggregation. Moreover, the phenol astonishingly activates neuronal autophagy
even in mice at advanced stage of pathology, where it increases histone 3 and 4 acetylation, which
matches both a decrease of histone deacetylase 2 expression and a significant improvement of synaptic
function. The occurrence of these functional, epigenetic, and histopathologic beneficial effects even at a
late stage of the pathology suggests that the phenol could be beneficial at the therapeutic, in addition to
the prevention, level.
 2015 Elsevier Inc. All rights reserved.1. Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder characterized by the occurrence of 2 main histopathologic
signs in the affected brain regions: extracellular amyloid plaques,
composed of deposits of the amyloid-ß (Aß) peptides, and intra-
cellular neurofibrillary tangles, composed of fibrillar polymers of
the hyperphosphorylated tau protein (Selkoe and Schenk, 2003).
The main component of the extracellular plaque deposits is a
polymeric fibrillar form of the 42 amino acid Aß peptide (Aß42)
generated by sequential proteolytic cleavage by ß- and g-secretases
of the amyloid precursor protein. Although the plaques are widely
considered as the main contributors to the functional alterations
and behavioral deficits that characterize AD (Haass, 2004), several
lines of evidence point to a key role played by the early oligomericoscience, Psychology, Drug
and Toxicology, University of
; fax: þ39 055 4271280.
enti).
ll rights reserved.Aß aggregates preceding the appearance of mature fibrils and/or
possibly leaked from the latter (Hayden and Teplow, 2013). Oligo-
meric tau aggregates and hyperphosphorylated tau tangles (Barten
et al., 2012; Gendron and Petrucelli, 2009) together with the effects
of Aß peptides on tau phosphorylation state and degradation are
also increasingly considered (Giacobini and Gold, 2013), leading to
include AD among the tauopathies (Wang and Liu, 2008).
Besides full-length Aß peptides, a variety of different N-trun-
cated Ab peptides have been identified within the cored and diffuse
amyloid plaques in the AD brain starting with amino residue Ala-2,
pyroglutamylated Glu-3, Phe-4, Arg-5, His-6, Asp-7, Ser-8, Gly-9,
Tyr-10, and pyroglutamylated Glu-11 (Antonios et al., 2013; Bayer
and Wirths, 2014; Lemere et al., 1996; Saido et al., 1995).
Aß peptides can undergo N-terminal truncation by 2 or by 10
amino acids and subsequent cyclization of resulting N-terminal
glutamate (E) to pyroglutamate (pE) which generates pE3-Aß(3-40/
42) and pE11-Aß(11-40/42) peptides that display a loss of 3 charges
and 6 charges, respectively with ensuing increase of their hydro-
phobicity (Gunn et al., 2010; Mori et al., 1992; Saido et al., 1995).
These shortened pyroglutamylated peptides are reported to be
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isoforms and to seed further Aß aggregation (He and Barrow, 1999;
Nussbaum et al., 2012; Schilling et al., 2008). It is unclear whether
pE3-Aß is present in early plaque deposits or it accrue later, and
some authors have proposed that pyroglutamylated-Aß (pE-Aß)
(40/42) peptides could be initiators of AD pathogenesis and others
report that Aß4-42 precedes pE3-Aß (Antonios et al., 2013; Jawhar
et al., 2011a; Schilling et al., 2008; Wirths et al., 2010).
The modification which originates the pE-Aß peptides is cata-
lyzed by glutaminyl cyclase (QC, also known as QPCT) both in vitro
(Schilling et al., 2004) and in vivo (Cynis et al., 2006, 2008; Nussbaum
et al., 2012; Schilling et al., 2008). In the mammalian brain, a phys-
iologically relevant neuronal expression of QC was described in the
hypothalamus, and enzyme involvement in neuropeptide and hor-
mone maturation was shown (Bockers et al., 1995; Fischer and
Spiess, 1987). In the AD brain, QC activity and pE-Aß levels are
increased by several folds (Schilling et al., 2008) and distinct types of
pE-Aß deposits, where pE3-Aß(3-42) predominates, have been
identified at sites of QC-immunoreactive neurons and in target fields
of QC-rich projection neurons (Hartlage-Rubsamen et al., 2011).
Chronic pharmacologic inhibition of QC (Schilling et al., 2008) or
suppression of its encoding gene (Alexandru et al., 2011; Wirths
et al., 2009) in transgenic mouse models of AD resulted in reduced
pE-Aß peptide generation and improved performance in cognitive
tasks, whereas QC overexpression worsened neuropathology and
cognitive dysfunction (Jawhar et al., 2011b).
We have recently reported that 8-week dietary supplementation
of oleuropein aglycone (OLE), a natural phenol (secoiridoid) abun-
dant in the extra virgin olive oil, improves learning and memory,
reduces de novo Aß42 deposition, favors preformed Aß42 plaque
disassembly and greatly stimulates the autophagic response in the
young and middle-aged TgCRND8 (Tg) mouse model of Aß depo-
sition (Grossi et al., 2013). Our aimwas to providemore information
on the molecular and biological basis of these effects by investi-
gating whether the same dietary supplementation of OLE resulted,
directly or indirectly, in a reduction of the toxic pE3-Aß peptide
deposits in the brain of the same Tg mouse model at different ages
corresponding to early, intermediate, and late stage of Aß deposi-
tion. We also checked the level of histone acetylation in the oldest
treated and untreated animals to ascertain whether the protective
effects of OLE supplementation also involved epigenetic modifica-
tions. In fact, recent data indicate that epigenetic changes are
implicated in learning and memory (Graff et al., 2012) and these
modifications have been suggested as potential targets for AD
therapeutics (Adwan and Zawia, 2013). Accordingly, we investi-
gated the functional effects of OLE in aged animals by assessing in
brain slices whether its administration in vitro was able to coun-
teract dysfunctions of transgene-induced long-term potentiation
(LTP) in the CA1 hippocampal area.
Our study provides evidence that the massive age-dependent
deposition of toxic pE3-Aß is strongly reduced in the TgCRND8
mice fed with a normal diet supplementedwith OLE and that such a
decrease likely reflects the parallel reduction of QC expression.
Furthermore, we show that, in our mouse model of Ab deposition,
autophagy activation, histone acetylation, and LTP facilitation un-
derlie the OLE-promoted benefits at the histopathologic and func-
tional level, suggesting new perspectives for AD not only at the
prevention but also at the therapeutic level.
2. Method
2.1. Ethics statement
Transgenic hemizygous CRND8male and femalemice, harboring
a double-mutant gene of APP695 (Chishti et al., 2001) with a (C57)/(C57/C3H) genetic background, and non-Tg hybrid (C57)/(C57/C3H)
wild type (wt) control littermate mice were used following the ECC
(DL 116/92, Directive 86/609/EEC) and National guidelines for ani-
mal care. The protocol was approved by the Committee on the
Ethics of Animal Experiments of the Italian Ministry of Health
(Permit Number: 283/2012-B).
2.2. Animals
The following 3 age groups of mice (n ¼ 6/group/genotype,
equally divided for sex) were used: 1.5 months old, 4 months old,
and 10 months old. As we have recently reported (Grossi et al.,
2013) each age group of mice was equally treated for 8 weeks
with a modified low-fat (5.0%) AIN-76A diet (10 g/d per mouse)
composed of 50.0% sucrose, 5.0% fat, 20.0% casein, 15.0% corn starch,
5.0% powdered cellulose, 3.5% AIN-76 mineral mix, 1.0% AIN-76A
vitamin mix, 0.3% DL-methionine, and 0.2% choline bitartrate
(Piccioni, Milan, Italy), either as such (untreated mice) or supple-
mented with OLE (50 mg/kg of diet) (OLE-fed mice). Such OLE dose
approximately corresponds to the amount that mice would ingest if
the 5.0% fat present in the diet consisted in an extra virgin olive oil
very rich in phenols (Galvano et al., 2007).
Additionally, 9-month-old untreated wt or Tg mice were used
for electrophysiological recordings (n ¼ 3e6 mice/group).
2.3. Oleuropein deglycosylation
Oleuropein (Extrasynthase, Genay Cedex, France) deglycosylation
was performed according to Konno et al. (1999) with minor modi-
fications. Briefly, a 10 mM solution of glycated oleuropein in 0.1 M
sodiumphosphate buffer, pH 7.0, was incubatedwith 6.0 I.U./mL of b-
glycosidase overnight at room temperature in the dark. The reaction
mixture was centrifuged at 10,000g for 15 minutes to precipitate the
aglycone. The complete oleuropein deglycosylation was confirmed
by assaying the glucose released in the supernatant with the Glucose
(HK) Assay Kit (Sigma-Aldrich, Milan, Italy). GC-MS analysis showed
the absence of any oleuropein in the precipitate and the substantially
total recover of OLE in the same precipitate. A 50 or 100 mM OLE
stock solution in dimethyl sulfoxide (DMSO) was stored protected
from light; the solution was diluted immediately before use in seed
oil (for mice feeding) or in buffer (for in vitro experiments).
2.4. In vitro aggregation of pE3-Aß and evaluation of aggregate
cytotoxicity
pE3-Aß (Anaspec Fremont, CA, USA) was dissolved to 1.0 mM in
hexafluoroisopropanol by brief sonication and kept overnight at 25 C.
Then the solution was divided into aliquots, hexafluoroisopropanol
was evaporated and the resulting filmwas maintained at20 C until
use. For pE3-Aß aggregation, the peptide, redissolved at 500 mM in
alkalinized CH3CN, was diluted to 25 mM in 10 mM phosphate buffer,
pH 7.7, containing 11 mM NaCl, as previously described for Aß42
(Rigacci et al., 2011) and 100 mMOLE (when present) was added. Such
OLE:peptide molar ratio (4:1) was chosen on the basis of our previous
results obtained with Aß42 (Rigacci et al., 2011). Higher molar ratios
could not be explored because of OLE interference in the circular di-
chroism (CD) signal, whereas lower ratios did not produce an evident
inhibition of aggregation. The samples were prepared at 4 C and then
incubated at 25 C for up to 4 hours. Far-UV CD analysis was per-
formed with a Jasco J-810 Spectropolarimeter equipped with a ther-
mostated cell-holder attached to a Thermo Haake C25P water-bath.
The spectra were acquired with 1.0 nm data pitch, 50 nm/min speed,
1.0 seconds response, and 10 accumulations. Background spectrawere
acquired for buffer with or without 100 mMOLE, and subtracted from
sample spectra. The same aggregates were diluted 1:50 in culture
Table 1
Antibodies used in the study
Antibody Specific Dilution Antigen retrieval for IHC Host Source
WB IHC
6E10 Residue 1e16 ß-amyloid ND 1:400 Citrate buffer pH ¼ 6,
formic acid 70% for 10 min
Mouse Covance, Priceton, NJ, USA
Ab42 Ab peptide, aa 1e42 ND 1:200 Rabbit Millipore, Billerica, MA, USA
Beclin 1 Beclin 1 protein ND 1:200 Citrate buffer pH ¼ 6 Rabbit Abcam, Cambridge, UK
Cathepsin B Procathepsin B and mature
cathepsin B
ND 1:100 Citrate buffer pH ¼ 6 Rabbit Millipore, Billerica, MA, USA
GFAP Glial fibrillary acidic protein ND 1:500 Rabbit Dako, Glostrup, Denmark
H3K9 Acetyl-histone H3 (Lys9) 1:1000 1:400 Citrate buffer pH ¼ 6 Rabbit Cell Signaling, Danvers, MA, USA
H4K5 Acetyl-histone H4 (Lys5) 1:1000 1:400 Citrate buffer pH ¼ 6 Rabbit Cell Signaling, Danvers, MA, USA
HDAC2 Histone deacetylase 2 1:1000 1:250 Citrate buffer pH ¼ 6 Rabbit Abcam, Cambridge, UK
LC3 Microtubule-associated protein
light chain 3
ND 1:200 Citrate buffer pH ¼ 6 Rabbit Novus Biologicals, Littleton, CO, USA
NeuN Neuronal nuclei ND 1:100 Citrate buffer pH ¼ 6 Mouse Millipore, Billerica, MA, USA
pE3-Aß (N3pE) Third N-terminal pyroglutamate
residue on Aß
ND 1:200 Citrate buffer pH ¼ 6 Rabbit IBL International, Hamburg, Germany
QC (QPCT) Glutaminyl cyclase 1:1000 1:100 Citrate buffer pH ¼ 6 Rabbit Sigma-Aldrich, Milan, Italy
SQSTM1/p62 SQSTM1/p62 protein ND 1:200 Citrate buffer pH ¼ 6 Mouse Abcam, Cambridge, UK
a-tubulin (HRP-conjugated) a-tubulin 1:5000 ND Mouse Proteintech, Chicago, IL, USA
Key: aa, amino acid; IHC, immunohistochemistry; H3K9, histone 3 acetylation on lysine 9; H4K5, histone 4 acetylation on lysine 5; ND, not done; QC, glutaminyl cyclase; WB,
Western blot.
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48 hours to evaluate their cytotoxicity by the MTT assay, as previously
described for Aß42 (Rigacci et al., 2011). As a control, cell aliquotswere
treated with the aggregation buffer, with or without OLE.
2.5. In vitro assay of glutaminyl cyclase inhibition
The assay was performed by using recombinant human QC (R&D
Systems, Minneapolis, MN, USA) and Q-7-amino-4-methylcoumarin
(AMC) (Bachem, Bubendorf, Switzerland) as a fluorogenic substrate,
following the instruction provided by R&D Systems. The reaction
mixture, containing 0.1 mg/mL QC and 50 mM Q-AMC (fluorescent
substrate) in 25 mM HEPES, pH 7.0, was incubated for 20 minutes at
room temperature with or without different concentrations (in the
1e10 mM range) of OLE. The reaction was stopped by boiling the
samples at 100 C for 5 minutes; then the samples were cooled on ice
for 3 minutes and an equal volume of 0.1 M Tris, 5.0 mM DTT, pH 9.0
containing 1.0 mg/mL recombinant human pyroglutamyl-peptidase-1
(R&D Systems) was added to release AMC. After 10 minutes (during
which the reaction was completed), 100 mL aliquots of the samples
were loaded in quadruplicate in a black 96-well plate and the increase
in fluorescence emission because of AMC cleavage was evaluated by
an automatic plate reader (BioRad, Hercules, CA, USA) (380nmEx/
460nmEm). Blanks with or without OLE were prepared in the absence
of enzymes. A sample supplemented with OLE after the boiling step
was also evaluated to exclude any effect of OLE on pyroglutamyl-
peptidase-1.
2.6. Animal tissue processing
The mice were sacrificed by cervical dislocation, and the brains
were rapidly removed and divided sagittally. For protein analysis,
cortical and hippocampal samples from one hemibrain were
immediately sectioned, snap-frozen, and stored at80 C. The other
hemibrain was postfixed for 48 hours in phosphate-buffered 4.0%
paraformaldehyde, pH 7.4, at 4 C, rinsed in phosphate buffered sa-
line (PBS) and embedded in paraffin for immunohistochemistry.
2.7. Immunohistochemistry and Western blotting
Immunohistochemical analyses were performed on 5.0 mm
coronal paraffin-embedded sections, as previously described(Fiorentini et al., 2010). The sections were incubated overnight
at 4 C with the primary antibodies (Abs) (Table 1) diluted in 0.1 M
PBS, pH 7.4, containing Triton X-100 (0.3%), and BSA (5.0 mg/mL).
For pE3-Aß and Ab plaque identification, tissue sections were
incubated for 1 hour with the biotinylated secondary Ab (Vector
Laboratories, Burlingame, CA, USA) diluted 1:1000 in 0.1 M PBS/BSA
(1.0 mg/mL); immunostaining was visualized using the avidin-
biotin system (Vectastain, Vector Laboratories) and 3,30- dia-
minobenzidine plus Nickel (DAB Kit) (Vector Laboratories) as the
chromogen.
Fluorescent immunohistochemistry experiments were carried
out as previously reported (Bellucci et al., 2007) The sections were
incubated for 1 hour with blocking solution (BS) containing 0.25%
Triton X-100, 5.0 g/L BSA, and 5.0% normal horse serum in 0.1 M
PBS, pH 7.4, and then overnight at 4 C with the primary Ab
(Table 1). On day 2, the sections were incubated for 2 hours in the
dark with the appropriate fluorescent secondary Ab (Alexa Fluor
594- 488- or 350-conjugated monoclonal anti-mouse and poly-
clonal anti-rabbit Ab, Invitrogen, New York, NY, USA) diluted 1:400
in BS. For double immunostaining, the sections were incubated
overnight with the second primary Ab in the dark at 4 C and, on
day 3, for 2 hours at room temperature with the second fluorescent
Ab diluted 1:400 in BS. The analysis of negative controls (not
treated with the primary Ab) was simultaneously performed to
exclude the presence of nonspecific immunofluorescence staining,
cross-immunostaining, or fluorescence bleed-through.
The sections were cover slipped using ProLong (Lyfe Technolo-
gies, New York, NY, USA) mounting medium with or without DAPI
for nuclear staining. Representative images were acquired by an
Olympus BX63 microscope coupled to CellSens Dimension Imaging
Software version 1.6 (Olympus, Milan, Italy) (Fiorentini et al., 2010).
ForWestern blotting analysis, tissue samples were homogenized
in ice-cold RIPA lysis buffer; then 40 mg of proteins were applied to
4%e12% Criterion XT Bis-Tris Gel (Novex NuPAGE, Lyfe Technolo-
gies) for electrophoresis with XT MES running buffer (Lyfe Tech-
nologies). The separated proteins were transferred onto 0.2 mm
nitrocellulose membrane by the iBlot dry blotting system (Invi-
trogen) and incubated overnight at 4 C with the primary Ab (see
Table 1). The day after, the blots were incubated for 1 hour with the
HRP-conjugated secondary Ab (Thermo Scientific, Waltham, MA,
USA) diluted 1:4000 in BS. The immunocomplexes were visualized
using enhanced chemiluminescence (Immobilon Western,
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350 system (GE Healthcare, Buckinghamshire, UK). Densitometric
band analysis was performed using the Image Quant TL software
version 7.0 (GE Healthcare). The bands were normalized to a-
tubulin. All primary Abs concentrations were titrated to provide
optimal staining (Table 1).
2.8. Determination of pE3-Aß and Ab42-plaque load
To quantify pE3-Ab and Aß42 plaque burden in untreated and
OLE-fed mice, cortices and hippocampi of the sections stained with
an anti-N3pE (Ab against pE3-Aß) and an anti-Ab42 Ab were digi-
tized and acquired with an Olympus BX63 microscope equipped
with the CellSens Dimension software (Olympus) as previously
reported. Six coronal brain sections taken at 60 mm intervals were
analyzed for each mouse (5e6 mice/group). Plaque number and
plaque areawere determined automatically. The brain regions were
selected on the basis of the mouse brain atlas (Paxinos and Franklin,
2001).
2.9. Mouse hippocampal slice preparation and electrophysiological
recordings
Hippocampal slices (400-mm thick) were superfused at a con-
stant flow rate of 2.0 mL/min with oxygenated (95% O2e5% CO2)
artificial cerebral spinal fluid (124 mM NaCl, 3.0 mM KCl, 1.25 mM
NaH2PO4, 2.0mMMgCl2, 2.4mMCaCl2, 26mMNaHCO3, and 10mM
D-glucose, pH 7.4). Test pulses (100 ms) were delivered through a
bipolar nichrome electrode positioned in the CA1 stratum radiatum
to stimulate Schaffer collateral and/or commissural fibers. Extra-
cellular field excitatory post-synaptic potentials (fEPSPs) were
evoked at 0.033 Hz and recorded with glass microelectrodes of
2e10 MU (Harvard Apparatus Ltd., Edenbridge, UK) filled with
150 mM NaCl, as previously described (Pugliese et al., 2009). The
responses were amplified (BM 622, Mangoni, Pisa, Italy), digitized
(sample rate, 33.33 kHz), and stored for subsequent analysis with
the LTP 2.30D program (Anderson and Collingridge, 2001). After the
responses were stabilized, input-output curves were recorded by
gradually increasing stimulus intensity. A test stimulus was chosen
at approximately 30%e40% of the maximum evoked responses. All
slices included in this study presented, under basal stimulation, a
single fEPSP not contaminated by multiple, back-propagating, so-
matic population spikes, which are an index of increased excit-
ability and are related to in vivo epileptic discharges (Arrieta-Cruz
et al., 2010; Palop et al., 2007). fEPSP slope or amplitude were
routinely measured and expressed as the percentage of the
respective 5 minutes averaged value preceding the exposure to OLE
and/or suberoylanilide hydroxamic acid (SAHA, Sigma-Aldrich)
treatment or LTP induction (baseline). LTP was induced by a 3-
theta burst stimulation (3-TBS) protocol (each burst consisted of 4
pulses at 100 Hz with a 200ms interburst interval) followed, after 1
hour, by a high-frequency stimulation (HFS) protocol, consisting of
100 pulses delivered at 100 Hz for 1 second. LTP was defined as an
increase by at least 20% of the fEPSP slope, lasting not less than 1
hour after train stimulation. To determine whether LTP magnitude
differed significantly between groups, average responses recorded
between 50 and 60 minutes after 3-TBS or HFS induction were
compared. Post-tetanic potentiation (PTP) was quantified as the
averaged fEPSP slope of the first 2 stimuli recorded after the in-
duction of each train.
OLE (50 mM) and SAHA (100 mM), dissolved in DMSO and
stored at 20 C, were daily diluted in artificial cerebral spinal fluid
to a final concentration of 50 mM (a dose known to produce sig-
nificant effects in cultured cells, that is, autophagy induction as
reported in Grossi et al., 2013) and 5.0 mM, respectively. The sliceswere incubated in the presence of OLE or SAHA for at least 1 hour
before electrophysiological recordings and superfused with either
substance for the entire time of the experiment. The final concen-
tration of DMSO (0.01% or 0.1%) used in our experiments did not
affect the slope nor the amplitude of evoked fEPSPs. For each slice
incubated in OLE or SAHA a corresponding control slice taken from
the same animal was analyzed. The effect of OLE on basal synaptic
activity was investigated by superfusing hippocampal slices with
50 mMOLE for at least 30minutes, without previous incubation. The
averaged slope of fEPSPs evoked 5 minutes before drug application
was compared with that recorded during the last 5 minutes of the
time of OLE application (30 minutes). Electrophysiological re-
cordings were carried out at 31 Ce32 C.
2.10. Liquid chromatographyemass spectrometry/mass
spectrometry analysis of OLE and its derivatives in the brain tissue
In a set of experiments we aimed to quantitatively determine
the brain concentration of OLE metabolites 2 hours after an acute
administration via gavage to wt mice of 60 mg/kg of OLE dissolved
in DMSO and diluted in seed oil (1:3) (OLE-treated, n ¼ 4) or of an
equal volume of vehicle (untreated, n ¼ 4). We used a previously
validated technique (Serra et al., 2012), specifically looking for OLE
and its main metabolites, hydroxytyrosol (HT), and homovanillic
acid (HVA). Themicewere sacrificed by cervical dislocation, and the
brains were rapidly removed and snap-frozen.
2.11. Drugs and reagents
Stock solutions of OLE were made in analytical grade DMSO and
HT and HVA (Sigma, MI, Italy) were prepared in HPLC grade meth-
anol. Further dilutions were made using HPLC grade methanol. All
chemicals and solvents were of the highest purity available from
commercial sources and used without any further purification.
2.12. Tissue sample preparation
Thawed brain sections (cerebral hemispheres) were weighed
and diluted with 0.5 mL H2O. The tissue was homogenized using a
mechanical homogenizer (UltraTurrex, IKA-Werke, Staufen, Ger-
many) followed by 10 minutes of intermittent ultrasonication in ice
bath. Samples were defatted using 1.0 mL of dichloromethane with
vigorous shaking for 5 minutes, followed by centrifugation at
3000 rpm for 10minutes. The aqueous upper phasewas transferred
to a new tube, and the chloroform extraction step was repeated 3
times. After the last extraction, methanol (200 mL) was added, and
the precipitates were removed by centrifugation at 13,200 rpm for
3 minutes. Then the samples were dried out and rehydrated with
100 mL acidified methanol (0.1% formic acid, vol/vol). To quantify
metabolites in treated animals, calibration curves of OLE, HT, and
HVA at concentrations 0, 0.1, 0.5, 1, 5, and 10 ng/L were prepared by
spiking chemical standards directly in brain tissue samples from 4
untreated mice. Spiked brain tissues were prepared exactly with
the same sample preparation of all other samples.
2.13. Data analysis
One-way analysis of variance, plus Bonferroni post hoc test, was
used to analyze aggregate cytotoxicity, enzyme inhibition, and
Western experiments and, plus Newman Keuls post hoc test, to
analyze LTP data. Unpaired 2-tailed Student t test was used to
analyze pE3-Aß and Aß42 plaque burden. Paired Student t test was
used to evaluate fEPSP potentiation after LTP induction. Statistical
analyses were carried out with GraphPad Prism version 5.0 for
Windows (San Diego, CA, USA), and the statistical significance was
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3. Results
3.1. OLE modifies pE3-Aß aggregation in vitro
Our previous data showed that OLE interferes with the aggre-
gation in vitro of Aß42 by skipping the formation of toxic species
(Rigacci et al., 2011). Therefore, initially we sought to assess
whether, and to what extent, OLE modified pE3-Aß aggregation as
well with respect to Aß42. To this purpose, 25 mM pE3-Aß was
incubated under aggregation conditions in the presence or in the
absence of 100 mMOLE, and its secondary structure was analyzed at
different aggregation times by CD. Immediately after dilution in
phosphate buffer, the pE3-Aß spectrum displayed the typical
feature of an unfolded peptide with a minimum around 200 nm
both in the absence and in the presence of OLE (Fig. 1A); however,
already after 1 hour of incubation a well-defined minimum around
218 nm (typical of b-structure) was evident in the pE3-Aß sample
without OLE but not in the sample containing OLE (Fig. 1B). The
aggregation kinetics of pE3-Aß was very fast; in fact, we previously
showed that a comparable structural transition of Aß42 was seen
after 24 hours of incubation at the same conditions (Rigacci et al.,
2011). After 4 hours of incubation in the presence or in the
absence of OLE, the spectra of pE3-Aß displayed a similar trend
(Fig. 1C), but in the absence of OLE the signal was considerably
reduced, suggesting peptide precipitation, in agreement with pre-
vious data relative to human islet amyloid polypeptide aggregation
in the presence or in the absence of OLE (Rigacci et al., 2010).
Therefore, our findings confirm previous data on Aß42 and human
islet amyloid polypeptide, suggesting that also in the case of pE3-AßFig. 1. OLE affects pE3-Aß aggregation and toxicity. (AeC) Far-UV CD analysis of 25 mM pE3-
immediately after peptide dilution in aqueous buffer (0 hours, panel A) and then after 1 hou
minimum from 200 nm to 218 nm indicates a shift from an unfolded to a b-sheet rich struc
or without OLE. Values are calculated respect to control, taken as 100%. Data are reported as
** p < 0.01 pE3-Ab treated cells versus control cells. Abbreviations: CD, circular dichroism; OLOLE does not completely inhibit but, rather, modifies the aggrega-
tion path.
The previously mentioned conclusion is supported by the
cytotoxicity analysis of the aggregates grown at the end of the CD
experiment, as assessed by the MTT test (Fig. 1D). In fact, we found
that the viability of SH-SY5Y neuroblastoma cells exposed for
48 hours to 0.5 mM pE3-Aß aggregates was significantly reduced
with respect to that of unexposed control cells; however, the
viability of the same cells exposed for the same time to pE3-Aß
aggregates grown in the presence of OLE was not significantly
different from that of unexposed control cells but significantly
different from that of pE3-Aß-treated cells (p < 0.05). We conclude
that, at our conditions, the pE3-Aß aggregates grown in the pres-
ence of OLE, but not those arising in the absence of the phenol, are
substantially devoid of toxicity to a culturedmodel of neuronal cells
most likely due to a different aggregation path skipping or reducing
the presence of toxic intermediates.
3.2. OLE reduces pE3-Aß burden in TgCRND8 mice
Once assessed that OLE interferes with pE3-Aß aggregation
in vitro and cytotoxicity, we moved to our Tg animal model fed for
8 weeks with the normal diet supplemented or not with OLE. At the
end of treatment, we first analyzed different brain areas of 3.5-, 6-,
and 12-month-old-Tg mice to check whether diet supplementation
with OLE resulted in any altered pE3-Aß load respect to untreated
age-matched Tg mice. As shown in the low and high magnification
photomicrographs in Fig. 2A, pE3-Aß immunoreactivity (IR)
increased with age in untreated Tg mice. In fact, in 3.5-month-old
Tg mice (either untreated or OLE-fed) very few or no pE3-Aß
immunoreactive plaques were detected in different brain areas.
However, in untreated 6-month-old Tg mice few and small-sizedAß aggregated in the absence or in the presence of 100 mM OLE. Spectra were acquired
r (B) and 4 hours (C) of incubation in aggregation conditions. The shift of the spectrum
ture. (D) MTT assay on SH-SY5Y cells exposed for 48 hours to 500 nM aggregates with
mean  SEM (n ¼ 4).  p < 0.05 pE3-Ab þ OLE treated cells versus pE3-Ab treated cells;
E, oleuropein aglycone; pE3-Aß, pyroglutamate-3 Aß; SEM, standard error of the mean.
Fig. 2. OLE reduces pE3-Aß and Aß42 plaque load in the cortex and hippocampus of TgCRND8 mice. (A) Representative photomicrographs of pE3-Aß and Aß42 immunopositive
deposits. (B) Quantitative analysis of pE3-Aß plaque area and plaque number in 6- and 12-month-old untreated and OLE-fed Tg mice (n ¼ 5/group, 6 sections/mouse) in the parietal
and piriform cortices and hippocampus. (C) pE3-Ab to Ab42 load ratio in untreated and OLE-fed Tg mice. (D) Quantitative analysis of Ab42 plaque burden in the parietal cortex and
hippocampus of untreated and OLE-fed 12-month-old Tg mice. Data are reported as mean values  SEM. Abbreviations: Hippo, hippocampus; OLE, oleuropein aglycone; P ctx,
parietal cortex; pE3-Aß, pyroglutamate-3 Aß; Pir ctx, piriform cortex; SEM, standard error of the mean. * p < 0.05, ** p < 0.01, *** p < 0.001.
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piriform, entorhinal, motor and parietal cortices andwithin the CA1
and dentate gyrus areas. Finally, in untreated 12-month-old mice alarge number of cored and diffuse pE3-Aß positive plaques of
different size and shape were detected throughout the cortical
areas as well as in the hippocampus and in some subcortical areas,
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the picture; in fact, the load of pE3-Aß positive plaques was reduced
and/or abolished in OLE-treated 6-month-old mice and strongly
reduced in OLE-treated 12-month-old mice (Fig. 2A). The quantita-
tive analysis of the pE3-Aß load carried out in the parietal and piri-
form cortices and in the hippocampus of 6- and 12-month-old Tg
mice (Fig. 2B) confirmed what was indicated by the images: in both
age groups of OLE-fed animals plaque load, in terms of plaque
number and plaque area, was significantly reduced, as compared
with age-matched untreated animals. Aß42 IR was also markedly
reduced in the parietal cortex of 12-month-old Tg mice fed with OLE
as compared with age-matched untreated Tg mice (Fig. 2A). Such a
reduction was confirmed by the quantitative analysis of Aß42-
immunopositive plaque number and area in the parietal cortex and
hippocampus (Fig. 2D).
Next, we evaluated the pE3-Aß to Aß42 plaque load area ratio in
the parietal cortex and hippocampus of 6- and 12-month-old ani-
mals (Fig. 2C). In the group of 6-month-old untreated Tg mice, the
pE3-Aß load in the parietal cortex was roughly comparable with
that of Aß42, with a pE3-Aß to Aß42 ratio close to 1, whereas it was
much higher (>2) in the hippocampus. In untreated 12-month-old
Tg mice both brain structures displayed a pE3-Aß load much higher
than that of Aß42, with an up to 6-fold pE3-Aß to Aß42 ratio
(Fig. 2C), indicating increased pE3-Aß deposition with age. When
we analyzed the same brain areas of OLE-fed Tgmice, we found that
in both age groups the pE3-Aß to Aß42 ratio was significantly
reduced (roughly ¼ 1), suggesting a strong activity of OLE against
pE3-Aß production and/or aggregation, in the latter case confirm-
ing the in vitro data. The overall reduction in amyloid plaque load in
the brains of OLE-fed 6- and 12-month-old Tg mice, as compared
with untreated Tg animals, was confirmed by 6E10 immunolabel-
ling, as shown in the hemispheres of 12-month-old mice (Fig. 3A).
Once established that OLE counteracts primarily pE3-Aß ag-
gregation in vivo we sought to assess the localization of the
aggregated pE3-Aß peptide (blue) within 6E10 (red) immuno-
positive plaques in 12-month-old Tg mice fed or not with OLE.
Fig. 3B shows a remarkable overlap of the blue and red fluorescence
in the entire plaque; however, the blue staining relative to pE3-Aß
is particularly intense in the core of the plaque, where no apparent
OLE effect is evident in spite of the reduction in size and disas-
sembly of plaques resulting from the treatment.
Overall, our results indicate that OLE, besides reducing Aß42
load, is even more effective in inhibiting the generation and/or
deposition of pE3-Aß in the brain tissue of aged animals but not the
localization in the plaque core of the residual fraction of its
aggregates.Fig. 3. 6E10 and pE3-Aß staining in untreated and OLE-fed TgCRND8 mice. (A) OLE administr
old TgCRND8 mice. (B) pE3-Aß (blue) and 6E10 (red) staining co-localizes in cored Aß deposi
Aß. (For interpretation of the references to color in this Figure, the reader is referred to the3.3. OLE reduces QC expression in 6- and 12-month-old TgCRND8
mice
It is known that pE3-Aß is generated both in vitro and in vivo via
QC-catalyzed cyclization of the N-terminal glutamate residues
present in the truncated Aß species (Cynis et al., 2008; Schilling
et al., 2004) and that both pE3-Aß levels and QC activity are
increased in the AD brain (Schilling et al., 2008). Therefore, we
firstly checked whether OLE was able to inhibit directly QC activity
in vitro by using recombinant QC and Q-AMC as a substrate. We
found that OLE, even at 10 mM concentration did not significantly
modify QC activity (fluorescence emission of AMC at the end of the
reaction in the presence of 10 mM OLE versus control, taken as 100:
96.13  26.15, n ¼ 3).
Once assessed that OLE does not inhibit the QC activity directly,
we sought to evaluatewhether the OLE-induced reduction of pE3-Aß
in tissue could, at least in part, be related to some impairment of QC
expression. We therefore performed an immunofluorescence anal-
ysis of QC in brain slices and aWestern blotting determination of QC
in brain extracts of the oldest groups of mice. As exemplified for the
12-month-old animals in Fig. 4A, a strong QC IR (green) was detected
throughout the cortical and hippocampal areas of untreated Tgmice;
this IR was diminished in all brain areas of OLE-fed Tg mice to levels
comparable with those detected in the brains of wt mice. Western
blotting analysis of QC levels confirmed these results showing sta-
tistically significant higher protein levels in the cortex and hippo-
campus of 6- and 12-month-old untreated Tgmicewith respect towt
and OLE-fed Tgmice (Fig. 4B). Finally, no significant differences in QC
protein levels were detected between wt and OLE-fed Tg mice.
Taken together, these data agree with those relative to the levels
of pE3-Aß in OLE-treated or untreated Tg mice, showing that the
heavier plaque load in the brains of 6- and 12-month-old Tg mice is
paralleled by a significant increase in QC expression, whereas both
are maintained at the control values by OLE supplementation.
QC IR was detected mainly in cells with neuronal morphology as
shown in the parietal cortex and in the hippocampus of Tg mice
(Fig. 5A) and in the co-localization staining between QC (green) and
NeuN (red) Abs (Fig. 5B). Interestingly, QC (green) and 6E10 (red) IR
also co-localized (yellow) in cored amyloid plaques (Fig. 5A,
arrowhead). In the radiatum and molecular layers of the hippo-
campus of untreated Tg mice, QC IR was detected also within cells
with glia morphology in the vicinity of 6E10-positive plaques (ar-
rows in Fig. 5A), as confirmed by the co-localization (yellow) be-
tween QC (red) and GFAP (green) staining (merged image plus DAPI
in Fig. 5C). Notably, no QC IR within glial cells was observed in OLE-
fed Tg mice (Fig. 5C).ation reduces 6E10 immunopositive plaque burden (red) in the hemibrain of 12-month-
ts of both Tg groups. Abbreviations: OLE, oleuropein aglycone; pE3-Aß, pyroglutamate-3
web version of this article.)
Fig. 4. OLE treatment restores QC expression to control levels in the brain of 6- and 12-month-old TgCRND8 mice. (A) Representative reconstructed photomicrographs of QC IR in the
cortex and hippocampus of 12-month-old mice; note, the less intense QC staining in OLE-fed Tg and untreated wt mice compared with untreated Tg mice. (B) Western blotting
analysis of QC protein levels in OLE-fed Tg and untreated wt and Tg mice, n ¼ 5e6 mice/group. Abbreviations: a-tub, a-tubulin; IR, immunoreactivity; OLE, oleuropein aglycone; QC,
glutaminyl cyclase; wt, wild type. * p < 0.05, ** p < 0.01, *** p < 0.001.
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reducing its QC-catalyzed production not through direct inhibition
of the enzyme activity but, most likely, by affecting enzyme
expression levels in neuronal and glial cells by a mechanism that
requires further investigation.
3.4. OLE induces autophagy in 12-month-old TgCRND8 mice
We have recently reported an intense activation of the
autophagosome-lysosome system in the cortex of 3.5- and 6-
month-old TgCRND8 mice, as well as in wt mice, fed with OLE.
Such an activation was considered a major responsible for the
marked reduction and disaggregation of Aß42 plaque deposits,
which also appeared less compact and more “fluffy” in OLE-fed Tg
mice (Grossi et al., 2013). Here, the same intense activation of
autophagy was found in the cortex of 12-month-old mice fed with
OLE. As shown in Fig. 6, an intense bright and punctate IR for Beclin
1 and LC3, 2 proteins involved in the initiation and execution of
autophagy, was detected in the soma, perikarya, and dendrites of
neurons in different layers of somatosensory and/or parietal (Fig. 6)
and piriform and/or entorhinal cortices of OLE-fed Tg mice, as
compared with untreated 12-month-old Tg mice. Although to a
lesser extent than in OLE-fed Tgmice, Beclin 1 and LC3 IRs were also
more intense in OLE-fed wt mice than in untreated animals, in
agreement with our previous data (Grossi et al., 2013), supporting a
general effect of OLE as an inducer of autophagy.The protective role of the increased autophagy in OLE-fed 12-
month-old mice was further assessed by checking whether it resul-
ted in enhanced degradation of autophagy substrates. As shown by
the yellow color in the merged images of Fig. 6, a significant co-
localization between cathepsin B immunoreactive bright puncta
and staining for p62, a cargo receptor targeting many cellular sub-
strates for autophagic degradation was found in small-sized lyso-
somes within cortical neurons of OLE-fed Tg animals; a similar
stainingwas found inwtmice, treatedoruntreatedwithOLE,whereas
little or no co-localization between cathepsin B and p62 staining was
detected inuntreated Tgmice. Altogether, thesefindings indicate that
the transgene-associated dysfunction of the autophagic pathway is
restored by OLE treatment and that the autophagosome-lysosome
fusion needed for cargo degradation is under way in OLE-fed 12-
month-old Tg mice as well as in age-matched wt mice.
3.5. OLE induces histone acetylation in 12-month-old TgCRND8
mice
Epigenetic changes, such as histone acetylation, are involved in
learning and memory and might be causally associated to AD patho-
genesis (Graff et al., 2012). The steady-state levels of histone acetyla-
tion at specific lysine residues result from concurrent acetylation and
deacetylation reactions catalyzed by histone acetyltransferases and
histone deacetylases, respectively. Histone acetylation ameliorates
cognitive deficits in AD animalmodels and its targeting is considered a
Fig. 5. OLE reduces QC IR in the brain of 12-month-old Tgmice. (A) QC IR (green) within neurons of the parietal cortex, the pyramidal cell layer of the hippocampus, and within 6E10 positive
plaques (red) (co-localization in yellow, arrowhead) in untreated and OLE-fed Tg mice. Note, in untreated Tg mice, QC expression also inside cells with glial morphology (arrows) in the close
proximity of Aß plaques; (B) Co-localization (yellow) between QC (green) andNeuN (red) Abs shows QC expression in neurons. (C) Double labeling immunohistochemistry with GFAP (green)
and QC (red) Abs plus DAPI (blue) revealed QC expression in astrocytes (yellow) within the radiatum and/or molecular layers of untreated Tg mice. Abbreviations: IR, immunoreactivity; OLE,
oleuropein aglycone; QC, glutaminyl cyclase. (For interpretation of the references to color in this Figure, the reader is referred to the web version of this article.)
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2013). Therefore, the search of a causative link of the beneficial ef-
fects of OLE on AD-like pathology of 12-month-old TgCRND8 mice
brought us to investigate whether OLE affected the level of histone
acetylation in the brains of our wt and Tg mice.
By using immunohistochemistry and Western blot analysis, we
found that the levels of histone 3 acetylation on lysine 9 (H3K9) and
of histone 4 acetylation on lysine 5 (H4K5) were higher in the brain
of OLE-fed Tgmice than in untreated littermates. As shown in Fig. 7A,
untreated Tg miceWestern blot analysis showed a trend of the H3K9
levels toward reduction and a significant reduction in the cortex and
hippocampus, respectively, as compared with untreated wt mice. In
the cortex of OLE-fed Tg mice, H3K9 levels were significantly
increased as compared with untreated Tg animals; in the hippo-
campus of OLE-fed mice, H3K9 levels were significantly increased as
compared with respective untreated animals. H4K5 acetylation
showed a trend toward a reduction, both in the cortex and in the
hippocampus, in the untreated Tg mice as compared with untreated
controls, although it appeared significantly increased in both brain
areas in OLE-fed Tg mice with respect to untreated Tg animals
(Fig. 7A). In agreement with the Western blot results, the IR of the
acetylated H3K9 and H4K5, as exemplified for H3K9 in Fig. 7B, was
increased in OLE-fed animals. In particular, in all animal groups H3K9
and H4K5 staining was detected in the entire cortex and in the
hippocampus and localized at the nuclear level, as shown in the
merged images of H3K9 staining (green) plus DAPI (blue) for Tg mice(Fig. 7B). The untreated Tg mice displayed an apparently less intense
H3K9 and H4K5 IR throughout the cortex and pyramidal layers of the
hippocampus as compared with the other groups.
Finally, we also checked the brain expression of histone deacety-
lase 2 (HDAC2) by Western blot and immunohistochemistry. We
found that HDAC2 levels were increased over 2.5-fold in the cortex
and over 1.5-fold in the hippocampus of untreated Tg mice as
compared with untreated wt mice (Fig. 8A), whereas in OLE-fed Tg
mice the treatment significantly counteracted those increases. In
brain areas of OLE-fed wt mice no significant effect of the treatment
on HDAC2 protein levels with respect to untreated controls was evi-
denced (Fig. 8A). Similarly to the Western blot data, HDAC2 IR was
strong throughout the cortical and hippocampal areas of untreated Tg
mice, and no differences were detected between OLE-fed Tg and wt
groups (Fig. 8B), confirming that OLE in some way affects the HDAC2
levels. Overall, the data reported in this section suggest that epige-
netic mechanisms could well contribute to the protective effects of
OLE in AD-like pathology.
3.6. OLE rescues HFS-induced LTP in aged TgCRND8 hippocampal slices
Once assessed that OLE protects Tg mice against Ab aggregation
by triggering protective responses, such as autophagy, that possibly
involve some epigenetic modulation, we investigated whether OLE
displayed any protective effect at the synaptic level bymeasuring LTP
in the hippocampus. Hippocampal LTP appears impaired in aged
Fig. 6. OLE induces activation of the autophagic machinery in the cortex of 12-month-old TgCRND8 mice. Representative images of the autophagic Beclin 1 and LC3 markers in the
somatosensory and/or parietal cortex of untreated and OLE-fed mice. Note, the intense bright and punctate neuronal staining for both proteins in the soma, perikarya, and dendrites
of OLE-fed Tg mice and, to a lesser extent, in the OLE-fed wt mice as compared with respective age-matched untreated mice. Autophagosome-lysosome fusion was rescued by OLE in
Tg mice and enhanced in the wt mice, as evidenced by the co-localization (yellow) of p62 (red) and cathepsin B (green) Abs in the 2 groups. In the untreated Tg mice, the
colocalization between the 2 Abs is almost absent. Abbreviations: Abs, antibodies; Cath B, cathepsin B; OLE, oleuropein aglycone. (For interpretation of the references to color in this
Figure, the reader is referred to the web version of this article.)
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previously showed that cognitive deficits are restored in young and/
or middle-aged TgCRND8mice following OLE administration (Grossi
et al., 2013). We therefore investigated whether OLE was able to
rescue the functional deficit, in terms of LTP, in aged Tg animals. LTP
induced in the absence of OLE by 3-TBS evoked a significant increase
of the fEPSP slope by 33.7%  4.1% and 25.3%  6.8% in wt and Tg
slices, respectively, in comparison with the relative average pre-
tetanus baseline (Fig. 9A and B). A single HFS train, administered
1 hour after the 3-TBS protocol, induced a further and persistent
increase of fEPSPs slope in wt slices (45% 11% vs. 3-TBS induction),
whereas in Tg slices it did not evoke any significant potentiation of
the fEPSP slope (Fig. 9A and B). These data support a functional
impairment of the hippocampal synaptic plasticity in Tg mice.
The occurrence of epileptic seizure events associated to Ab
deposition has been already reported in vivo in this mouse strain
(Del Vecchio et al., 2004); thus, the presence of multiple contami-
nating spikes, an in vitro epileptic-like activity (Palop et al., 2007),
in the fEPSP after both tetanic protocols was evaluated. The regis-
tration of multiple spikes after 3-TBS was 20% and 50% in the wt
(n ¼ 8) and Tg (n ¼ 12) slices, respectively, and after HFS was 33%
and 64% in the wt and Tg slices, respectively, indicating that
TgCRND8 mice show an increased sensitivity to develop in vitro
epileptic-like activity after tetanic stimulation.
Next, we evaluated the effects of 50 mM OLE superfusion on LTP
induction and maintenance in hippocampal slices of Tg and wt mice.
We found that OLE did not significantly modify themagnitude of LTP
induced by 3-TBS protocol (47.2%  7.1%) in Tg slices (Fig. 9A and B),
whereas it completely restored the HFS-induced potentiation of
fEPSP slope (55.7%  16.1%) (Fig. 9A and B). These results show that
LTPs resulting from either 3-TBS or HFS stimulation are differently
affected by the genotype and OLE application. In wt slices (n¼ 3), nosignificant effect of OLE application was observed on fEPSP slope
potentiation after 3-TBS (26.4% 8.4% increase) or HFS (24.6% 9.9%
increase) induction. To exclude an effect of the phenol per se on
hippocampal neurotransmission, in a set of experiments OLE was
acutely applied for 30 minutes in wt and Tg slices. No changes in
fEPSP slope or amplitude were observed (n ¼ 3/genotype). Inter-
estingly, OLE-treated Tg slices showed a reduced epileptic-like ac-
tivity after tetanic stimulation in comparison with untreated Tg
slices, because only 40% of slices displayed multiple spikes after
either 3-TBS or HFS protocols. Next, considering the data indicating
that HDAC2 inhibition ameliorated the cognitive deficits in AD ani-
mal models (Govindarajan et al., 2013; Sung et al., 2013) and that in
our Tg mice OLE increased histone acetylation, we checked whether
the HDAC2 inhibitor SAHA reproduced OLE effects in rescuing HFS-
induced LTP in hippocampal Tg slices. As shown in Fig. 9A and B,
we found that the LTP patterns in the presence of SAHAwere similar
to those recorded in the presence of OLE. In fact, in Tg mice SAHA did
not significantly modify the magnitude of LTP induced by 3-TBS
stimulation, but it significantly potentiated the HFS-induced fEPSP
responses (36.9%  24.7%; Fig. 9A and B).
The early phase of synaptic potentiation after a tetanic stimu-
lation is known as PTP, which is an index of short-term plasticity.
Our PTP analysis showed significant differences between slices
taken fromwt and Tg animals. Moreover, in Tg slices the significant
reduction in peak PTP levels induced by either 3-TBS (72.3%  11%)
or HFS (96.2%  13%), as compared with respective wt littermates
(112.3%  19% and 148.8%  13.2%) (Fig. 9C) was restored to control
values by both OLE and SAHA (Fig. 9C). Overall, these data indicate
that in Tg slices OLE restores HFS-induced LTP as well as 3-TBS- and
HFS-evoked PTPs, likely due to HDAC2 inhibition, suggesting for the
first time that OLE can play an important role in rescuing functional
synaptic activity.
Fig. 7. OLE enhances H3K9 and H4K5 acetylation in 12-month-old TgCRND8 mice. (A) Western blotting quantitative analysis revealed a trend to a decrease in the cortex and a
significant reduction in H3K9 levels in the hippocampus of untreated Tg mice compared with untreated wt mice. In the OLE-fed Tg mice, a statistically significant increase in H3K9
levels was found in the cortex and hippocampus as compared with untreated Tg mice. In the hippocampus, OLE administration significantly increases H3K9 levels also in wt mice as
compared with untreated wt mice (n ¼ 5e6 mice/group). Similarly, Western blotting analysis revealed a statistically significant increase in H4K5 levels in the cortex and hippo-
campus of OLE-fed Tg mice compared with untreated Tg mice. (B) Note, an increased H3K9 IR in the cortex and hippocampus of OLE-fed Tg mice compared with untreated Tg mice.
The nuclear localization of H3K9 (green) is shown in merged images with the nuclear marker DAPI (blue) for OLE-fed and untreated Tg mice (right panels). Abbreviations: a-tub,
a-tubulin; H3K9, histone 3 acetylation on lysine 9; H4K5, histone 4 acetylation on lysine 5; OLE, oleuropein aglycone; wt, wild type. * p < 0.05, ** p < 0.01, *** p < 0.001. (For
interpretation of the references to color in this Figure, the reader is referred to the web version of this article.)
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administration of OLE in wt mice
It is known that intestinal OLE is rapidly adsorbed in the plasma
of both rats and humans, distributed to various tissues, including
brain, conjugated and metabolized in a number of compounds
including HT, HVA and elenolic acid, and excreted in the urine (De
Bock et al., 2013; Serra et al., 2012). We therefore sought to quantifyby liquid chromatographyemass spectrometry/mass spectrometry
(LC-MS/MS) the concentrations of OLE and its major metabolites HT
and HVA in the brains of OLE-administered mice. Two hours after
an acute gavage administration of 60 mg/kg of OLE, the brain
concentrations of HT and HVA were 0.050  0.002 and 0.066 
0.004 nmol/g tissue, respectively. The concentration of OLE was
below our detection limit and no specific peak of OLE was identi-
fied; however, we cannot exclude that OLE as such could reach
Fig. 8. OLE administration reduces HDAC2 expression in TgCRND8 mice. (A) Western blotting analysis of HDAC2 protein levels in untreated and OLE-fed wt and Tg mice. The increase
of HDAC2 protein levels in untreated Tg mice, as compared with wt groups, was rescued to normal values in OLE-fed Tg mice, both in the cortex and hippocampus, n ¼ 5e6 mice/
group. (B) Brain immunohistochemistry of HDAC2 (green) shows a bright and intense IR in untreated TgCRND8 mice as compared with all other groups. Merged HCDA2 (green) plus
DAPI (blue) images in the right panels show the nuclear localization of HDCA2. Abbreviations: a-tub, a-tubulin; IR, immunoreactivity; OLE, oleuropein aglycone; wt, wild type. * p <
0.05, *** p < 0.001. (For interpretation of the references to color in this Figure, the reader is referred to the web version of this article.)
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thanks to its lipophilicity. No OLE metabolites were detected in the
untreated animals. Fig. 10 shows extracted ion chromatograms of
the specific HT and HVA transitions in both untreated (panel A) and
OLE-treated animals (panel B).
4. Discussion
The TgCRND8 mouse strain is widely used as a model of Aß
deposition inADstudies. In thismodel,Aßdeposits increaseover timeand become robust by 7e9 months of age (Bellucci et al., 2007; Rosi
et al., 2010). We have previously reported that OLE administration
in young and middle-aged TgCRND8 mice results in remarkably
beneficial behavioral, molecular, and histopathologic effects, sug-
gesting that it could be useful to treat patients with presymptomatic
orearlyAD (Grossi et al., 2013).Here,weextended to agedTgmice our
previous study on OLE protection to young and middle-aged Tg mice
and showed that the same dietary supplementation ofOLE has strong
functional andhistopathologic beneficial effects even at a late stage of
the pathology, characterized by a huge presence of Ab and pE3-Ab
Fig. 9. OLE restores LTP in CA1 hippocampal slices of aged TgCRND8 mice. (A) Time course of averaged fEPSP slope before and after LTP induced by 3-TBS protocol followed by HFS
protocol. Tg hippocampal slices were exposed to 50 mM OLE or 5 mM SAHA, 1 hour before and during all electrophysiological recordings. Upper panels show superimposed example
traces taken at representative time points indicated on the graph. Calibration: 1 mV, 10 ms. (B) Quantitative LTP analysis 1 hour after 3-TBS and HFS induction. (C) Comparison of PTP
responses induced by 3-TBS and HFS protocols. In each slice, the PTP value was taken as the slope of the first 2 fEPSPs following each train. In parentheses is the number of slices.
* p < 0.05, ** p < 0.01, *** p < 0.001. Abbreviations: fEPSP, extracellular field excitatory postsynaptic potential; HFS, high-frequency stimulation; LTP, long-term potentiation; OLE,
oleuropein aglycone; PTP, post-tetanic potentiation; SAHA, suberoylanilide hydroxamic acid; 3-TBS, 3-theta burst stimulation.
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our data support a multifunctional activity underlying the beneficial
effects of this natural polyphenol.
pE3-Ab has been reported to be amajor component of b-amyloid
plaques and vessel deposits in AD brains; it has also been suggested
that pE3-Ab plays an early and seminal role in Ab oligomerization
and aggregation due to its high aggregation propensity (Frost et al.,
2013). Moreover, in AD patients a better correlation seems to exist
between decline in Mini-Mental State Examination and elevated
pE3-Ab, rather than load of deposits of unmodified Ab (Morawski
et al., 2014). In contrast to humans, in many transgenic animal
models pE3-Ab deposition often occurs later than general Ab
deposition with the age of onset varying in different mouse models
(Frost et al., 2013).
In the present study, the expression of pE3-Ab was investigated
in the brain of untreated and OLE-fed TgCRND8 mice at the initial,
intermediate, and late stage of plaque deposition. Very few pE3-Ab
immunopositive plaques were detected in the piriform and/or en-
torhinal cortex of 3.5-month-old untreated Tg mice; then at the ageof 6 months, the number of pE3-Ab plaques slightly increased and
extended to the entire cortical mantle, mostly in the piriform and/
or entorhinal and parietal cortices and in the hippocampus. Finally,
in 12-month-old mice a huge deposition of pE3-Ab was detected
throughout the brain being particularly intense in all cortical and
hippocampal areas. However, Tg animals supplemented with OLE
for 8 weeks displayed a massive reduction of pE3-Ab deposits both
in the 6 and in the 12 months age group. This finding likely resulted
from prevention of new amyloid deposition and disaggregation of
preformed deposits, leading to a significant reduction of pE3-Ab
plaque size and number. For what the prevention of pE3-Ab
deposition by OLE administration is concerned, this could result
both from inhibition of aggregation by the phenol and its metabo-
lites, as suggested by the results of our in vitro experiments, and from
inhibition of QC-catalyzed pE3-Ab generation. Indeed, we found that
the age-related increase of QC and pE3-Ab deposition found in the
cortex and hippocampus of untreated TgCRND8 mice, which recalls
the pattern found in the brain of AD patients (Schilling et al., 2008),
was fully counteracted by OLE administration.
Fig. 10. Brain HT and HVA LC-MS/MS chromatograms in OLE-treated and untreated mice. Selected reaction monitoring experiments show that HT and HVA are not present in the
brain of mice treated with vehicle (A) whereas they are well depicted in OLE-treated mice (B). Abbreviations: cps, counts per second; HT, hydroxytyrosol; HVA, homovanillic acid;
OLE, oleuropein aglycone.
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Ab42 deposits in TgCRND8 mice at early and middle stage of amy-
loid pathology (Grossi et al., 2013), suggesting protection against Ab
toxicity. Our present findings show that OLE administration coun-
teracts the growth of pE3-Ab aggregates, even in the advanced and
late stage of Aß deposition, suggesting a possible therapeutic effect,
in addition to the proposed neuroprotective one.
Besides interfering with Ab aggregation, we found that OLE
administration triggers several other modifications in the brains of
aged mice, likely concurring to determine its overall healthy effect.
As reported for young andmiddle-agedmice (Grossi et al., 2013), an
astonishing activation of the autophagic lysosome system was
observed also in 12-month-old Tg mice and, to a lesser extent, in
age-matched wt controls. These data agree with a similar behavior
displayed also by other natural phenols (Li et al., 2011; Vingtdeux
et al., 2010) and, in our case, suggest that this pathway is
involved in the removal of toxic Aß aggregates also in the advanced
stage of the disease.
We also found a previously unknown epigenetic effect following
OLE administration, consisting in an increase of histone 3 and 4
acetylation which correlated with a significant decrease in HDCA2
protein level. Chemical modifications of histones, including acety-
lation, methylation, phosphorylation, biotinylation, and ubiquiti-
nation, play a fundamental role in the regulation of gene expression
throughout life (Henning et al., 2013). Histone acetylation is
thought to be associated with an “open” chromatin conformation
and transcriptional activation, whereas histone deacetylation isconsidered to be involved in transcriptional repression resulting
from a “closed” chromatin structure (Wang et al., 2013). Protein
acetylation level is the result of the dynamic interplay of the ac-
tivities of protein acetylases and deacetylases. In AD brains, the
HDCA2 protein levels are increased (Graff et al., 2012) and the ho-
meostasis of histone 3 acetylation is disrupted by soluble Aß
(Lithner et al., 2013). Similar epigenetic alterations occurred in our
untreated Tg mice, as shown by the increased HDCA2 protein levels
and by the reduced level of histone 3 and 4 acetylation throughout
the cortex and the hippocampus. In the nervous system, histone
acetylation has been associated with the facilitation of learning and
memory (Graff et al., 2011); accordingly, overexpression of HDAC2
in mice impairs memory and the chronic administration of the
HDAC inhibitors SAHA or sodium butyrate enhances cognition
(Govindarajan et al., 2011; Kilgore et al., 2010).
In the light of these pieces of evidence, the ability of OLE
administration to completely reverse the transgene-associated
deregulation of the levels of histone acetylation appears of partic-
ular relevance. Inhibition of HDAC expression and activity by other
natural phenols has previously been reported (Lee et al., 2011;
Thakur et al., 2012). More generally, the epigenetic effects of
OLE agree with similar data previously reported for other phenols
and polyphenols, including epigallocatechin-3-gallate, curcumin,
and resveratrol mainly for what their anti-cancer and immune-
modulatory potential is concerned (Wang et al., 2014; Zhang
et al., 2013). In general, epigenetic mechanisms have been
hypothesized in the modulation of the immune response and
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polyphenol-targeted epigenetics as an attractive approach for dis-
ease prevention and intervention (Pan et al., 2013). More recently,
aberrant epigenetic posttranslational modifications of proteins are
emerging as important elements in the pathogenesis of neurologic
diseases and their treatment and as a potential new approach for
prevention of neurodegeneration. In particular, current evidence
suggests that pharmacologically targeting histone deacetylases
may be of potential benefit in the treatment of such diseases (Gray,
2011). This view is supported by recent data on epigenetic sup-
pression of neuroligin 1, a postsynaptic protein found in central
excitatory synapses, indicating that amyloid-induced neuro-
inflammation in rats enhances the activity of the HDAC2-MeCP2
co-repressor complex suppressing neuroligin 1 expression, with
glutamatergic dysfunction in the hippocampus and memory defi-
cits. These data provide new clues to explain the benefits associated
with HDAC inhibition (Bie et al., 2014).
Our results support OLE beneficial effects even at the functional
level. In fact, OLE administration apparently reestablished the
pattern of neuronal activity, able to induce short- and long-term
synaptic plasticity phenomena, in CA1 hippocampal slices from
aged Tgmice. Moreover, OLEwas also able to reduce the appearance
of in vitro seizure-like activity observed inmost of the Tg slices after
both tetanic protocols, which may contribute to the epileptic ac-
tivity described in vivo in this mouse strain (Del Vecchio et al.,
2004). The different sensitivity to distinct patterns of high fre-
quency stimulation in Tg mice is in line with several results indi-
cating that Ab42 peptide significantly blocks synaptic plasticity
induced by HFS but not by TBS or other theta-burst stimulations
(Fitzjohn et al., 2000; Smith et al., 2009). Both OLE and the HDAC
inhibitor SAHA were able to restore HFS-induced LTP as well as 3-
TBS- and HFS-induced PTPs. Altogether, these findings suggest
that epigenetic mechanisms underlie the OLE-associated synaptic
functional improvement.
5. Conclusion
In conclusion, our previous (Grossi et al., 2013) and present data
do indicate that OLE or its main metabolites produced after OLE
administration, as shown by our LC-MS/MS data, improve memory
and behavioral performance; they do this by acting as multifunc-
tional drugs that restore, at least in part, in the brain of a mouse
model of AD different dysfunctional pathways by interfering with
Aß aggregation as well as with signaling and epigenetic pathways.
At present, the identified cellular targets include plaque deposition,
size, and compactness, the pE3-Aß to Aß42 ratio, the inflammatory,
the autophagic and lysosomal responses and the synaptic function.
Although more knowledge is needed to describe in depth the mo-
lecular and cellular mechanisms underlying these effects, particu-
larly the epigenetic modifications, our results suggest that OLE
administration could be considered as a new approach to prevent
and, possibly, treat AD.
Disclosure statement
The authors declare that they have no conflicts of interest.
Acknowledgements
The authors thank Dr P.St.G. Hyslop and Dr D. Westaway for
supplying the TgCRND8 mouse strain. This work was supported by
the Regione Toscana: “Programma per la Ricerca Regionale in
Materia di Salute 2009,” by the ECRF 2010-2011 and the Università
degli Studi di Firenze.References
Adwan, L., Zawia, N.H., 2013. Epigenetics: a novel therapeutic approach for the
treatment of Alzheimer’s disease. Pharmacol. Ther. 139, 41e50.
Alexandru, A., Jagla, W., Graubner, S., Becker, A., Bauscher, C., Kohlmann, S.,
Sedlmeier, R., Raber, K.A., Cynis, H., Ronicke, R., Reymann, K.G., Petrasch-
Parwez, E., Hartlage-Rubsamen, M., Waniek, A., Rossner, S., Schilling, S.,
Osmand, A.P., Demuth, H.U., von Horsten, S., 2011. Selective hippocampal neu-
rodegeneration in transgenic mice expressing small amounts of truncated Abeta
is induced by pyroglutamate-Abeta formation. J. Neurosci. 31, 12790e12801.
Anderson, W.W., Collingridge, G.L., 2001. The LTP program: a data acquisition pro-
gram for on-line analysis of long-term potentiation and other synaptic events.
J. Neurosci. Methods 108, 71e83.
Antonios, G., Saiepour, N., Bouter, Y., Richard, B.C., Paetau, A., Verkkoniemi-Ahola, A.,
Lannfelt, L., Ingelsson, M., Kovacs, G.G., Pillot, T., Wirths, O., Bayer, T.A., 2013. N-
truncated Abeta starting with position four: early intraneuronal accumulation
and rescue of toxicity using NT4X-167, a novel monoclonal antibody. Acta
Neuropathol. Commun. 1, 56.
Arrieta-Cruz, I., Wang, J., Pavlides, C., Pasinetti, G.M., 2010. Carvedilol reestablishes
long-term potentiation in a mouse model of Alzheimer’s disease. J. Alzheimers
Dis. 21, 649e654.
Barten, D.M., Fanara, P., Andorfer, C., Hoque, N., Wong, P.Y., Husted, K.H.,
Cadelina, G.W., Decarr, L.B., Yang, L., Liu, V., Fessler, C., Protassio, J., Riff, T.,
Turner, H., Janus, C.G., Sankaranarayanan, S., Polson, C., Meredith, J.E., Gray, G.,
Hanna, A., Olson, R.E., Kim, S.H., Vite, G.D., Lee, F.Y., Albright, C.F., 2012.
Hyperdynamic microtubules, cognitive deficits, and pathology are improved in
tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-
241027. J. Neurosci. 32, 7137e7145.
Bayer, T.A., Wirths, O., 2014. Focusing the amyloid cascade hypothesis on N-trun-
cated Abeta peptides as drug targets against Alzheimer’s disease. Acta Neuro-
pathol. 127, 787e801.
Bellucci, A., Rosi, M.C., Grossi, C., Fiorentini, A., Luccarini, I., Casamenti, F., 2007.
Abnormal processing of tau in the brain of aged TgCRND8 mice. Neurobiol. Dis.
27, 328e338.
Bie, B., Wu, J., Yang, H., Xu, J.J., Brown, D.L., Naguib, M., 2014. Epigenetic suppression
of neuroligin 1 underlies amyloid-induced memory deficiency. Nat. Neurosci. 17,
223e231.
Bockers, T.M., Kreutz, M.R., Pohl, T., 1995. Glutaminyl-cyclase expression in the
bovine/porcine hypothalamus and pituitary. J. Neuroendocrinol. 7, 445e453.
Chishti, M.A., Yang, D.S., Janus, C., Phinney, A.L., Horne, P., Pearson, J., Strome, R.,
Zuker, N., Loukides, J., French, J., Turner, S., Lozza, G., Grilli, M., Kunicki, S.,
Morissette, C., Paquette, J., Gervais, F., Bergeron, C., Fraser, P.E., Carlson, G.A.,
George-Hyslop, P.S., Westaway, D., 2001. Early-onset amyloid deposition and
cognitive deficits in transgenic mice expressing a double mutant form of am-
yloid precursor protein 695. J. Biol. Chem. 276, 21562e21570.
Cynis, H., Scheel, E., Saido, T.C., Schilling, S., Demuth, H.U., 2008. Amyloidogenic
processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl
cyclase in generation of pyroglutamate-modified amyloid-beta. Biochemistry
47, 7405e7413.
Cynis, H., Schilling, S., Bodnar, M., Hoffmann, T., Heiser, U., Saido, T.C., Demuth, H.U.,
2006. Inhibition of glutaminyl cyclase alters pyroglutamate formation in
mammalian cells. Biochim. Biophys. Acta 1764, 1618e1625.
De Bock, M., Thorstensen, E.B., Derraik, J.G., Henderson, H.V., Hofman, P.L.,
Cutfield, W.S., 2013. Human absorption and metabolism of oleuropein and
hydroxytyrosol ingested as olive (Olea europaea L.) leaf extract. Mol. Nutr. Food
Res. 57, 2079e2085.
Del Vecchio, R.A., Gold, L.H., Novick, S.J., Wong, G., Hyde, L.A., 2004. Increased
seizure threshold and severity in young transgenic CRND8 mice. Neurosci. Lett.
367, 164e167.
Fiorentini, A., Rosi, M.C., Grossi, C., Luccarini, I., Casamenti, F., 2010. Lithium im-
proves hippocampal neurogenesis, neuropathology and cognitive functions in
APP mutant mice. PLoS One 5, e14382.
Fischer, W.H., Spiess, J., 1987. Identification of a mammalian glutaminyl cyclase
converting glutaminyl into pyroglutamyl peptides. Proc. Natl. Acad. Sci. U. S. A
84, 3628e3632.
Fitzjohn, S.M., Morton, R.A., Kuenzi, F., Davies, C.H., Seabrook, G.R., Collingridge, G.L.,
2000. Similar levels of long-term potentiation in amyloid precursor protein
-null and wild-type mice in the CA1 region of picrotoxin treated slices. Neurosci.
Lett. 288, 9e12.
Frost, J.L., Le, K.X., Cynis, H., Ekpo, E., Kleinschmidt, M., Palmour, R.M., Ervin, F.R.,
Snigdha, S., Cotman, C.W., Saido, T.C., Vassar, R.J., George-Hyslop, P., Ikezu, T.,
Schilling, S., Demuth, H.U., Lemere, C.A., 2013. Pyroglutamate-3 amyloid-beta
deposition in the brains of humans, non-human primates, canines, and Alz-
heimer disease-like transgenic mouse models. Am. J. Pathol. 183, 369e381.
Galvano, F., La Fauci, L., Graziani, G., Ferracane, R., Masella, R., Di Giacomo, C.,
Scacco, A., D’Archivio, M., Vanella, L., Galvano, G., 2007. Phenolic compounds
and antioxidant activity of Italian extra virgin olive oil Monti Iblei. J. Med. Food
10, 650e656.
Gendron, T.F., Petrucelli, L., 2009. The role of tau in neurodegeneration. Mol. Neu-
rodegener. 4, 13.
Giacobini, E., Gold, G., 2013. Alzheimer disease therapyemoving from amyloid-beta
to tau. Nat. Rev. Neurol. 9, 677e686.
Govindarajan, N., Agis-Balboa, R.C., Walter, J., Sananbenesi, F., Fischer, A., 2011. So-
dium butyrate improves memory function in an Alzheimer’s disease mouse
I. Luccarini et al. / Neurobiology of Aging 36 (2015) 648e663 663model when administered at an advanced stage of disease progression.
J. Alzheimers Dis. 26, 187e197.
Govindarajan, N., Rao, P., Burkhardt, S., Sananbenesi, F., Schluter, O.M., Bradke, F.,
Lu, J., Fischer, A., 2013. Reducing HDAC6 ameliorates cognitive deficits in a
mouse model for Alzheimer’s disease. EMBO Mol. Med. 5, 52e63.
Graff, J., Kim, D., Dobbin, M.M., Tsai, L.H., 2011. Epigenetic regulation of gene expres-
sion in physiological and pathological brain processes. Physiol. Rev. 91, 603e649.
Graff, J., Rei, D., Guan, J.S., Wang, W.Y., Seo, J., Hennig, K.M., Nieland, T.J., Fass, D.M.,
Kao, P.F., Kahn, M., Su, S.C., Samiei, A., Joseph, N., Haggarty, S.J., Delalle, I.,
Tsai, L.H., 2012. An epigenetic blockade of cognitive functions in the neuro-
degenerating brain. Nature 483, 222e226.
Gray, S.G., 2011. Epigenetic treatment of neurological disease. Epigenomics 3,
431e450.
Grossi, C., Rigacci, S., Ambrosini, S., Ed Dami, T., Luccarini, I., Traini, C., Failli, P.,
Berti, A., Casamenti, F., Stefani, M., 2013. The polyphenol oleuropein aglycone
protects TgCRND8 mice against Aß plaque pathology. PLoS One 8, e71702. In
Press.
Gunn, A.P., Masters, C.L., Cherny, R.A., 2010. Pyroglutamate-Abeta: role in the nat-
ural history of Alzheimer’s disease. Int. J. Biochem. Cell Biol. 42, 1915e1918.
Haass, C., 2004. Take fiveeBACE and the gamma-secretase quartet conduct Alz-
heimer’s amyloid beta-peptide generation. EMBO J. 23, 483e488.
Hartlage-Rubsamen, M., Morawski, M., Waniek, A., Jager, C., Zeitschel, U., Koch, B.,
Cynis, H., Schilling, S., Schliebs, R., Demuth, H.U., Rossner, S., 2011. Glutaminyl
cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-
Abeta deposits in hippocampus via distinct cellular mechanisms. Acta Neuro-
pathol. 121, 705e719.
Hayden, E.Y., Teplow, D.B., 2013. Amyloid beta-protein oligomers and Alzheimer’s
disease. Alzheimers Res. Ther. 5, 60.
He, W., Barrow, C.J., 1999. The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides
found in senile plaque have greater beta-sheet forming and aggregation pro-
pensities in vitro than full-length A beta. Biochemistry 38, 10871e10877.
Henning, S.M., Wang, P., Carpenter, C.L., Heber, D., 2013. Epigenetic effects of green
tea polyphenols in cancer. Epigenomics 5, 729e741.
Jawhar, S., Wirths, O., Bayer, T.A., 2011a. Pyroglutamate amyloid-beta (Abeta): a
hatchet man in Alzheimer disease. J. Biol. Chem. 286, 38825e38832.
Jawhar, S., Wirths, O., Schilling, S., Graubner, S., Demuth, H.U., Bayer, T.A., 2011b.
Overexpression of glutaminyl cyclase, the enzyme responsible for pyrogluta-
mate A{beta} formation, induces behavioral deficits, and glutaminyl cyclase
knock-out rescues the behavioral phenotype in 5XFAD mice. J. Biol. Chem. 286,
4454e4460.
Kilgore, M., Miller, C.A., Fass, D.M., Hennig, K.M., Haggarty, S.J., Sweatt, J.D.,
Rumbaugh, G., 2010. Inhibitors of class 1 histone deacetylases reverse contex-
tual memory deficits in a mouse model of Alzheimer’s disease. Neuro-
psychopharmacology 35, 870e880.
Kimura, R., MacTavish, D., Yang, J., Westaway, D., Jhamandas, J.H., 2012. Beta
amyloid-induced depression of hippocampal long-term potentiation is medi-
ated through the amylin receptor. J. Neurosci. 32, 17401e17406.
Konno, K., Hirayama, C., Yasui, H., Nakamura, M., 1999. Enzymatic activation of
oleuropein: a protein crosslinker used as a chemical defense in the privet tree.
Proc. Natl. Acad. Sci. U. S. A 96, 9159e9164.
Lee, S.J., Krauthauser, C., Maduskuie, V., Fawcett, P.T., Olson, J.M., Rajasekaran, S.A.,
2011. Curcumin-induced HDAC inhibition and attenuation of medulloblastoma
growth in vitro and in vivo. BMC Cancer 11, 144.
Lemere, C.A., Lopera, F., Kosik, K.S., Lendon, C.L., Ossa, J., Saido, T.C., Yamaguchi, H.,
Ruiz, A., MartInez, A., Madrigal, L., Hincapie, L., Arango, J.C., Anthony, D.C.,
Koo, E.H., Goate, A.M., Selkoe, D.J., Arango, J.C., 1996. The E280A presenilin 1
Alzheimer mutation produces increased A beta 42 deposition and severe
cerebellar pathology. Nat. Med. 2, 1146e1150.
Li, W., Zhu, S., Li, J., Assa, A., Jundoria, A., Xu, J., Fan, S., Eissa, N.T., Tracey, K.J.,
Sama, A.E., Wang, H., 2011. EGCG stimulates autophagy and reduces cytoplasmic
HMGB1 levels in endotoxin-stimulated macrophages. Biochem. Pharmacol. 81,
1152e1163.
Lithner, C.U., Lacor, P.N., Zhao, W.Q., Mustafiz, T., Klein, W.L., Sweatt, J.D.,
Hernandez, C.M., 2013. Disruption of neocortical histone H3 homeostasis by
soluble Abeta: implications for Alzheimer’s disease. Neurobiol. Aging 34,
2081e2090.
Morawski, M., Schilling, S., Kreuzberger, M., Waniek, A., Jager, C., Koch, B., Cynis, H.,
Kehlen, A., Arendt, T., Hartlage-Rubsamen, M., Demuth, H.U., Rossner, S., 2014.
Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-beta load
and cognitive decline in Alzheimer’s disease. J. Alzheimers Dis. 39, 385e400.
Mori, H., Takio, K., Ogawara, M., Selkoe, D.J., 1992. Mass spectrometry of purified
amyloid beta protein in Alzheimer’s disease. J. Biol. Chem. 267, 17082e17086.
Nussbaum, J.M., Schilling, S., Cynis, H., Silva, A., Swanson, E., Wangsanut, T.,
Tayler, K., Wiltgen, B., Hatami, A., Ronicke, R., Reymann, K., Hutter-Paier, B.,
Alexandru, A., Jagla, W., Graubner, S., Glabe, C.G., Demuth, H.U., Bloom, G.S.,2012. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated
amyloid-beta. Nature 485, 651e655.
Palop, J.J., Chin, J., Roberson, E.D., Wang, J., Thwin, M.T., Bien-Ly, N., Yoo, J., Ho, K.O.,
Yu, G.Q., Kreitzer, A., Finkbeiner, S., Noebels, J.L., Mucke, L., 2007. Aberrant
excitatory neuronal activity and compensatory remodeling of inhibitory hip-
pocampal circuits in mouse models of Alzheimer’s disease. Neuron 55, 697e711.
Pan, M.H., Lai, C.S., Wu, J.C., Ho, C.T., 2013. Epigenetic and disease targets by poly-
phenols. Curr. Pharm. Des. 19, 6156e6185.
Paxinos, G., Franklin, K.B.J., 2001. The Mouse Brain in Stereotaxic Coordinates. Ac-
ademic Press.
Pugliese, A.M., Traini, C., Cipriani, S., Gianfriddo, M., Mello, T., Giovannini, M.G.,
Galli, A., Pedata, F., 2009. The adenosine A2A receptor antagonist ZM241385
enhances neuronal survival after oxygen-glucose deprivation in rat CA1 hip-
pocampal slices. Br. J. Pharmacol. 157, 818e830.
Rigacci, S., Guidotti, V., Bucciantini, M., Nichino, D., Relini, A., Berti, A., Stefani, M.,
2011. Abeta(1-42) aggregates into non-toxic amyloid assemblies in the pres-
ence of the natural polyphenol oleuropein aglycon. Curr. Alzheimer Res. 8,
841e852.
Rigacci, S., Guidotti, V., Bucciantini, M., Parri, M., Nediani, C., Cerbai, E., Stefani, M.,
Berti, A., 2010. Oleuropein aglycon prevents cytotoxic amyloid aggregation of
human amylin. J. Nutr. Biochem. 21, 726e735.
Rosi, M.C., Luccarini, I., Grossi, C., Fiorentini, A., Spillantini, M.G., Prisco, A., Scali, C.,
Gianfriddo, M., Caricasole, A., Terstappen, G.C., Casamenti, F., 2010. Increased
Dickkopf-1 expression in transgenic mouse models of neurodegenerative dis-
ease. J. Neurochem. 112, 1539e1551.
Saido, T.C., Iwatsubo, T., Mann, D.M., Shimada, H., Ihara, Y., Kawashima, S., 1995.
Dominant and differential deposition of distinct beta-amyloid peptide species,
A beta N3(pE), in senile plaques. Neuron 14, 457e466.
Schilling, S., Hoffmann, T., Manhart, S., Hoffmann, M., Demuth, H.U., 2004. Gluta-
minyl cyclases unfold glutamyl cyclase activity under mild acid conditions. FEBS
Lett. 563, 191e196.
Schilling, S., Zeitschel, U., Hoffmann, T., Heiser, U., Francke, M., Kehlen, A., Holzer, M.,
Hutter-Paier, B., Prokesch, M., Windisch, M., Jagla, W., Schlenzig, D., Lindner, C.,
Rudolph, T., Reuter, G., Cynis, H., Montag, D., Demuth, H.U., Rossner, S., 2008.
Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer’s
disease-like pathology. Nat. Med. 14, 1106e1111.
Selkoe, D.J., Schenk, D., 2003. Alzheimer’s disease: molecular understanding pre-
dicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol. 43, 545e584.
Serra, A., Rubio, L., Borras, X., Macia, A., Romero, M.P., Motilva, M.J., 2012. Distri-
bution of olive oil phenolic compounds in rat tissues after administration of a
phenolic extract from olive cake. Mol. Nutr. Food Res. 56, 486e496.
Smith, J.P., Lal, V., Bowser, D., Cappai, R., Masters, C.L., Ciccotosto, G.D., 2009.
Stimulus pattern dependence of the Alzheimer’s disease amyloid-beta 42
peptide’s inhibition of long term potentiation in mouse hippocampal slices.
Brain Res. 1269, 176e184.
Sung, Y.M., Lee, T., Yoon, H., DiBattista, A.M., Song, J.M., Sohn, Y., Moffat, E.I.,
Turner, R.S., Jung, M., Kim, J., Hoe, H.S., 2013. Mercaptoacetamide-based class II
HDAC inhibitor lowers Abeta levels and improves learning and memory in a
mouse model of Alzheimer’s disease. Exp. Neurol. 239, 192e201.
Thakur, V.S., Gupta, K., Gupta, S., 2012. Green tea polyphenols increase p53 tran-
scriptional activity and acetylation by suppressing class I histone deacetylases.
Int. J. Oncol. 41, 353e361.
Vingtdeux, V., Giliberto, L., Zhao, H., Chandakkar, P., Wu, Q., Simon, J.E., Janle, E.M.,
Lobo, J., Ferruzzi, M.G., Davies, P., Marambaud, P., 2010. AMP-activated protein
kinase signaling activation by resveratrol modulates amyloid-beta peptide
metabolism. J. Biol. Chem. 285, 9100e9113.
Wang, J.Z., Liu, F., 2008. Microtubule-associated protein tau in development,
degeneration and protection of neurons. Prog. Neurobiol. 85, 148e175.
Wang, J., Yu, J.T., Tan, M.S., Jiang, T., Tan, L., 2013. Epigenetic mechanisms in Alz-
heimer’s disease: implications for pathogenesis and therapy. Ageing Res. Rev.
12, 1024e1041.
Wang, M., Yu, T., Zhu, C., Sun, H., Qiu, Y., Zhu, X., Li, J., 2014. Resveratrol triggers
protective autophagy through the ceramide/Akt/mTOR pathway in melanoma
B16 cells. Nutr. Cancer 66, 435e440.
Wirths, O., Bethge, T., Marcello, A., Harmeier, A., Jawhar, S., Lucassen, P.J.,
Multhaup, G., Brody, D.L., Esparza, T., Ingelsson, M., Kalimo, H., Lannfelt, L.,
Bayer, T.A., 2010. Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic
and familial Alzheimer’s disease cases. J. Neural Transm. 117, 85e96.
Wirths, O., Breyhan, H., Cynis, H., Schilling, S., Demuth, H.U., Bayer, T.A., 2009.
Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal
neurological deficits in a transgenic mouse model. Acta Neuropathol. 118,
487e496.
Zhang, B.K., Lai, Y.Q., Niu, P.P., Zhao, M., Jia, S.J., 2013. Epigallocatechin-3-gallate
inhibits homocysteine-induced apoptosis of endothelial cells by demethylation
of the DDAH2 gene. Planta Med. 79, 1715e1719.
